Effects of concurrent TP53 mutations on the efficacy and prognosis of targeted therapy for advanced EGFR mutant lung adenocarcinoma

Lung cancer has high mortality rates caused by the low early diagnostic rate, being prone to distant metastasis and drug resistance during treatment[1]. EGFR is the most frequent driving gene in lung adenocarcinoma, and it has been detected in almost 40-50% Asian lung adenocarcinoma patients[2]. 19 exon deletion (19del) and 21 exon L858R mutations (L858R) are the most common EGFR mutation types and considered sensitive to EGFR-TKIs[3]. Although having EGFR mutations can predict a favorable TKIs response, acquired resistance will eventually develop.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research